News
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...
A new bladder cancer device called TAR-200 kept most patients cancer-free and surgery-free in a trial, with few side effects ...
News-Medical.Net on MSN22h
New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback